Effects of long‐term paroxetine or bupropion treatment on puberty onset, reproductive and feeding parameters in adolescent male rats by Yardımcı, Ahmet et al.
Andrologia. 2019;e13268.	 wileyonlinelibrary.com/journal/and	 	 | 	1 of 11
https://doi.org/10.1111/and.13268
© 2019 Blackwell Verlag GmbH
1  | INTRODUC TION
Puberty is a developmental period associated with significant so‐
matic and behavioural changes, where adequate reproductive ca‐
pacity is reached and the gonadal axis is fully awakened (Roa et al., 
2010). The age of puberty can vary depending on factors such as 
race, gender, genetic, nutrition, living conditions and secular trends 
(Ercan, 2005; Parent et al., 2003). With the development of living 
conditions and socioeconomic status in many countries around 
the world, it was reported that the age of menarche comes to ear‐
lier to an average of 3.6 months per 10 years in every 100 years 
(Keizer‐Schrama & Mul, 2001; Ong, Ahmed, & Dunger, 2006). It is 
thought that these changes occurred in the onset of puberty due 
to the secular trends are caused by postnatal environmental fac‐
tors (Domine, Parent, Rasier, Lebrethon, & Bourguignon, 2006). We 
think that one of these factors may be antidepressants because an‐
tidepressant use in children and adolescents has increased signifi‐
cantly in recent years (Bachmann et al., 2016). In addition, it was 
reported that before adolescence (<12 years of age), boys took more 
prescribed antidepressant drugs than girls (O'Sullivan et al., 2015). 
Whether or not postnatal antidepressants’ use can lead to preco‐
cious or delayed puberty is almost unknown.
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Abstract
Antidepressant use in adolescents has become more common in recent years. We 
have found several studies stating that prenatal antidepressant exposure can lead to 
delayed or earlier puberty onset but there was no study on postnatal paroxetine or 
bupropion. The main aim of this study was to investigate the effect of postnatal ex‐
posure to bupropion or paroxetine on puberty onset, reproductive and feeding re‐
sults. The male rats (n = 8/group) aged 21 days were exposed to paroxetine (3.6 mg/
kg) or bupropion (17 mg/kg) orally by gastric gavage every day from postnatal day 
21–90. Also, control group received only saline orally as a vehicle. Postnatal exposure 
to bupropion or paroxetine delayed puberty onset compared to control group, but it 
was not significant. Sperm counts were significantly lower in the paroxetine and bu‐
propion groups compared to control group. Sperm motility was significantly lower in 
only bupropion group. In addition, sperm motility was lower in paroxetine group, but 
it was not significant. In the histopathological examination, there was damage to the 
testicular structure in both treatments. Taken together, our result indicates that post‐
natal paroxetine or bupropion exposure may affect puberty onset and contribute to 
the impairment in fertility in male rats.
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Selective serotonin reuptake inhibitors (SSRIs), including paroxe‐
tine, are the most widely used antidepressants in the world (Krasowska, 
Szymanek,	Schwartz,	&	Myśliński,	2007).	They	 increase	 the	 level	of	
extracellular serotonin (5‐hydroxytryptamine, 5‐HT) by inhibition of 
5‐HT reuptake. This effect is thought to be the main mechanism, and 
how they show exactly their effects is not known yet (Sanchez, Reines, 
& Montgomery, 2014). Increases in 5‐HT levels in some specific re‐
gions of the brain allow the SSRIs to demonstrate therapeutic prop‐
erties. However, the effect of SSRIs on the 5‐HT transporter is not 
specific to a certain brain region. They increase 5‐HT levels in many 
regions of the nervous system. As a result, some side effects occur 
(Carrasco & Sandner, 2005). In regard to these antidepressants’ ef‐
fects on the puberty onset, there are few studies about only prenatal 
treatment (dos Santos et al., 2016; Moore et al., 2015).
In regard to bupropion, it is used in the treatment of depression 
and	some	psychiatric	disorders	(Fava	et	al.,	2005).	 It	 is	known	that	
bupropion shows its antidepressant effect by inhibiting dopamine 
and norepinephrine reuptake (Belson & Kelley, 2002; Dwoskin, 
Rauhut, King‐Pospisil, & Bardo, 2006). It is also the only antidepres‐
sant with double effect on norepinephrine–dopamine. Whether or 
not there is a serotonergic activity is not known yet (Demyttenaere 
&	 Jaspers,	 2008).	 Unlike	 many	 other	 antidepressants,	 bupropion	
does	 not	 cause	 weight	 gain	 and	 even	 provides	 weight	 loss	 (Fava	
et al., 2005). There is only one study about the effects of prenatal 
bupropion treatment on the puberty onset (De Long et al., 2013). 
However, postnatal effects of paroxetine or bupropion treatment on 
the puberty onset are almost unknown.
The main aim of this study was to determine the effects of post‐
natal long‐term paroxetine or bupropion treatment on the puberty 
onset and reproductive parameters.
2  | MATERIAL S AND METHODS
2.1 | Animals and treatments
Twenty‐four (21 days of age) male Sprague‐Dawley rats, weighing 
40	±	2	g,	were	 obtained	 from	 the	University	 of	 Firat	 Experimental	
Research	Unit	 (FUDAM).	 This	 study	was	 done	 at	 FUDAM	 in	 com‐
pliance with the guidelines for the ethical use of laboratory ani‐
mals	that	were	approved	by	the	Firat	University	Ethic's	Committee	
of Experimental Animals Research as of 11.06.2014, number 140 
(Elazig, Turkey). The rats were individually housed in standard cages 
for 12:12‐hr light‐dark cycles with constant temperature (21 ± 1°C) 
and humidity (55 ± 5%). Pelleted food and tap water were provided 
ad libitum. Changes in food and water consumption and body weights 
of animals were recorded between 10.00 and 12.00 a.m. each day 
for 69 days. The groups were determined as control, paroxetine 
and bupropion groups (n = 8 in each group). Paxil tablets containing 
20	mg	 paroxetine	 (SmithKline	 Beecham	 Pharmaceuticals,	 UK)	 and	
Wellbutrin	XL	(Aspen	Bad	Oldesloe	GmbH	in	Bad	Oldesloe,	Germany)	
containing 150 mg bupropion were supplied from a local pharmacy. 
The required amount of paroxetine and bupropion was crushed in 
mortar separately and solved in saline. Both antidepressants were 
prepared just before treatment. Paroxetine (3.6 mg/kg) and bupro‐
pion (17 mg/kg) were given orally by gastric gavage between 10.00 
and 12.00 a.m. every day from postnatal day (pnd) 21 (weaning day) 
to pnd 90. In addition, control group received only saline as a vehi‐
cle. Both drugs’ doses were effective doses for rats and, based on 
previous	studies	 (Inass,	Hassan,	Fouad,	&	El‐Komey,	2005;	Terry	&	
Katz, 1997) and tablet form of both drugs, were used to mimic the 
administration way in humans. In addition, in order to determine 
puberty onset age of animals, we assessed preputial separation, 
morphological signs of the puberty in male rats, from pnd 30 to pu‐
berty. The experiment finished at pnd 90. At the end of the study, the 
animals were first anesthetised with 60 mg/kg ketamine and 5 mg/
kg xylazine cocktail intramuscularly and were placed in supine po‐
sition. Then, the abdomen was opened by incision and 5‐ml blood 
sample was taken from abdominal aorta to blood tubes for hormone 
analyses and then centrifuged at 1792 g for 5 min at +4°C. Serum 
samples	were	stored	in	−20°C	until	the	luteinising	hormone	(LH),	fol‐
licle‐stimulating	hormone	(FSH),	leptin	and	testosterone	ELISA	were	
performed.
2.2 | Reproductive organs weights
After opening the abdomen by incision, left and right epididymis, 
testicular tissues, prostate and seminal gland were taken respec‐
tively. In order to prevent the loss of motility, the left epididymis 
was first weighed, and then, the other reproductive organs were 
weighed	 as	wet,	 and	 the	 data	were	 recorded.	 Finally,	 the	 animals	
were then decapitated and the procedure terminated.
2.3 | Epididymal sperm analyses
All sperm analyses were performed using the methods reported in 
the previous study (Turk et al., 2008). The epididymal sperm con‐
centration was determined by a hemacytometer using a modified 
method. The right epididymis was finely chopped in a petri dish in 
1 ml saline with the aid of a scalpel. It was then completely crushed 
with a tweezers for 2 min and then incubated for 4 hr at room 
temperature to allow all spermatozoa to pass from the epididymal 
tissue to the fluid. After incubation, the epididymal tissue‐fluid 
mixture was filtered through a strainer to separate the superna‐
tant from the tissue particles. The supernatant fluid containing all 
epididymal spermatozoa was drawn into the capillary tube until 
line 0.5 of the pipette designed to count the red blood cells. The 
solution containing 0.595 M sodium bicarbonate, 1% formalin and 
0.025% eosin was drawn into the bulb up to 101 lines of the pi‐
pette. The contents of the pipette were mixed. Sufficient solu‐
tion was then blown from the pipette to ensure that the diluents 
containing no spermatozoa were flushed from the capillary. This 
gave a dilution rate of 1:200 in this solution. Approximately 10 ml 
of the diluted sperm suspension was transferred to both count‐
ing chambers of an Improved Neubauer (Deep 1/10 mm; LABART, 
Darmstadt,	Germany)	and	allowed	to	stand	for	5	min.	The	sperm	
cells in both chambers were counted with a light microscope at 
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200× magnification. The percentage of forward progressive sperm 
motility was assessed using a light microscope with a heated stage. 
For	this	process,	a	slide	was	placed	on	a	 light	microscope	with	a	
heated stage warmed up to 37°C, and then, several droplets of 
Tris buffer solution (0.3 M Tris(hydroxymethyl)aminomethane, 
0.027 M glucose, 0.1 M citric acid) were dropped on the slide and 
a very small droplet of fluid obtained from left cauda epididymis 
with a pipette was added to the Tris buffer solution and mixed by 
a cover‐slip. The percentage of forward progressive sperm motil‐
ity was assessed visually at 400× magnification. Motility estimates 
were conducted from three different fields in each sample. The 
mean of the three successive estimations was used as the final 
motility score. In order to determine the percentage of morpho‐
logically abnormal spermatozoa, the slides stained with eosineni‐
grosin (1.67% eosin, 10% nigrosin and 0.1 M sodium citrate) were 
prepared. The slides were then viewed under a light microscope at 
400× magnification. A total of 300 sperm cells was examined on 
each slide (2,400 cells in each group), and the head, tail and total 
abnormality rates of spermatozoa were expressed as a percentage.
2.4 | Histopathological examination
After decapitation, testis tissues were fixed in Bouin's solution. 
Tissues were embedded in paraffin by applying routine tissue prepa‐
ration techniques. The 5‐µm‐thick tissue sections were taken from 
paraffin blocks, and then, tissues were stained by periodic acid–
Schiff (PAS) technique. All of tissue sections were examined and pho‐
tographed by Olympus BH2 photo‐microscope. Histopathological 
changes were revealed by counting them on randomly selected 
twenty areas at 20× magnification for each group.
2.5 | Hormone measurements
Serum	FSH	and	LH	hormone	levels	were	determined	by	ELISA,	based	
on the method reported by a previous study with some modifica‐
tions (Pappa, Seferiadis, Marselos, Tsolas, & Messinis, 1999). Initially, 
pre‐incubation was made with standards and serum samples in the 
96‐well plates (Nunc, Roskilde, Denmark), coated with rat LH and 
FSH	antibodies,	and	antigen	binding	was	achieved	with	primary	an‐
tibodies at solid phase. Washing was then carried out on the plates, 
and secondary antibody‐conjugated streptavidin was added to each 
well and colour formation was achieved using tetramethylbenzi‐
dine as the substrate. After incubation, the plates were assayed at 
450	nm	in	ELISA	(Biotek,	Synergy	HT,	USA).	Rat	FSH	and	LH	primary	
antibodies	(rabbit	anti‐rat	LH	and	rabbit	anti‐rat	FSH)	were	supplied	
from	Dr.	AF	Parlow	(National	Institute	of	Diabetes	and	Digestive	and	
Kidney Diseases National Hormone and Peptide Program, National 
Institutes	 of	 Health,	 USA).	 Secondary	 antibodies	 (goat	 anti‐rabbit	
IgG)	and	its	conjugate	streptavidin	peroxidase	were	purchased	from	
Sigma	 (Sigma‐Aldrich,	Taufkirchen,	Germany).	The	 inter‐	and	 intra‐
assay	variation	coefficients	for	both	LH	and	FSH	were	<8%.	Leptin	
and testosterone ELISA kits were supplied from the YH Biosearch 
Laboratory (Shanghai, China). In leptin analysis, serum samples were 
first incubated with leptin monoclonal antibodies previously added 
to the plates. Biotin‐linked anti‐LEP antibodies were then added to 
the wells, and coupling with streptavidin–HRP was achieved. After 
incubation, washing was carried out, and colour formation was ac‐
complished by the addition of substrates A and B. The same proce‐
dure was repeated for testosterone measurement. After incubation, 
the plates were assayed at 450 nm in ELISA (Thermo Scientific, 
USA).	The	sensitivity	of	the	measurement	to	leptin	was	0.05	ng/ml	
and 0.25 nmol/L for testosterone. The inter‐assay variation coeffi‐
cients for both leptin and testosterone were below 12%, and the 
intra‐assay variation coefficients were below 10%.
2.6 | Statistical analysis
All values were expressed as mean ± standard error of mean (SEM). 
Statistical analyses and graphs were as follows: SPSS 21.0 and 
Origin 6.0. One‐way ANOVA post hoc Tukey's HSD and Pearson's 
chi‐square tests were used for evaluation of the data. In all analyses, 
p < 0.05 was considered statistically significant.
TA B L E  1   Effects of paroxetine or bupropion on male rats’ 
puberty onset age
Groups
Puberty onset 
age (day)
Control 47.12 ± 0.91
Paroxetine 50.75 ± 1.63
Bupropion 49.87 ± 1.10
Note. One‐way ANOVA and post hoc Tukey's HSD tests were used for 
evaluation of the data. Data are represented as mean ± SEM.
F I G U R E  1   Effects of paroxetine 
or bupropion on puberty onset are 
documented in male rats (pnd 21–90). 
(a) Preputial separation and (b) pubertal 
weights are presented for animals treated 
with paroxetine or bupropion (one‐way 
ANOVA followed by post hoc Tukey's 
HSD test). n = 8 for each group
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3  | RESULTS
3.1 | Effects of paroxetine or bupropion on puberty 
parameters and reproductive organs
Treatment of paroxetine or bupropion caused the puberty onset a 
slight shift from 47.12 ± 0.91 to 50.75 ± 1.63 and 49.87 ± 1.10 days 
respectively. However, the extents of puberty timing were not sig‐
nificant (Table 1). While all of the animals in control showed complete 
preputial separation on 51 days, animals treated with paroxetine or 
bupropion presented complete preputial separation at 57 days and 
55 days, respectively, and there was a shift towards to the right in 
puberty	onset	day	 (Figure	1a).	The	starting	days	of	puberty	onset	
were 44 days in the control group, 46 days in the paroxetine group 
and 47 days in the bupropion group, and pubertal weights were not 
changed	 by	 bupropion	 or	 paroxetine	 treatment	 (Figure	 1b).	 Also,	
there was no statistically significant difference in testis, epididymis, 
prostate and seminal vesicle weights (Table 2).
3.2 | Effects of paroxetine or bupropion on LH, FSH, 
testosterone and leptin levels
Treatment of bupropion caused a significant rise in LH levels 
(3.66 ± 0.1 vs. 2.73 ± 0.1 for the control group, p	<	0.01;	Figure	2a).	
However, the LH value of the paroxetine (2.87 ± 0.1 vs. 2.73 ± 0.1) 
group was not statistically significant compared with the control 
group. In addition, there was no statistically significant differ‐
ence	 between	 the	 control	 group	 and	 other	 groups	 at	 FSH	 levels	
(Figure	2b).	The	testosterone	levels	were	39.69	±	2.27	for	the	con‐
trol group. Bupropion group (47.74 ± 2.33) was found to be sig‐
nificantly increased compared to the control group in testosterone 
levels (p ˂	0.05;	Figure	2c).	There	was	no	significant	difference	be‐
tween the paroxetine group (43.35 ± 1.60) and the control group in 
testosterone	levels	(Figure	2c).	Also,	leptin	levels	were	not	changed	
by	paroxetine	or	bupropion	treatment	(Figure	2d).
3.3 | Effects of paroxetine or bupropion on 
sperm parameters
In the rats administered paroxetine or bupropion, cauda epididy‐
mal sperm count was significantly lower in both treatment groups 
TA B L E  2   Effects of paroxetine or bupropion on male rats’ 
reproductive organs’ weights
Variable Control Paroxetine Bupropion
Testis (mg) 1037 ± 62.31 993.7 ± 31.89 860.4 ± 51.96
Epididymis 
(mg)
342.5 ± 12.48 322.9 ± 14.62 363.9 ± 14.83
Prostate 
(mg)
107.8 ± 10.82 94 ± 8.73 98.5 ± 3.98
Seminal 
vesicle 
(mg)
303.1 ± 19.67 281 ± 9.29 295.1 ± 11.55
Note. One‐way ANOVA and post hoc Tukey's HSD tests were used for 
evaluation of the data. Data are represented as mean ± SEM. n = 8 for 
each group.
F I G U R E  2   Effects of paroxetine or 
bupropion	on	(a)	LH	levels,	(b)	FSH	levels,	
(c) testosterone levels and (d) leptin levels 
in male rats. *p ˂	0.05;	versus	control	
group, #p	˂	0.01;	versus	control	group	
(one‐way ANOVA followed by post hoc 
Tukey's HSD test). n = 8 for each group
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compared with the control group (42 ± 7.12 and 38 ± 6.32 vs. 
107.25 ± 7.09 × 106/ml, respectively, p < 0.001). Also, sperm mo‐
tility was significantly lower in the bupropion group (64.28 ± 4.80 
vs. 80 ± 1.88% for the control group, p < 0.05). The effects of 
paroxetine or bupropion on sperm parameters are presented in 
Table 3.
3.4 | Effects of paroxetine or bupropion on food and 
water intake and body weight
There was no statistically significant difference between the con‐
trol	 group	 and	 other	 groups	 at	 food	 (Figure	 3a)	 and	water	 intake	
(Figure	3b)	in	the	69‐day	period.	However,	in	the	paroxetine	group	
Variable Control Paroxetine Bupropion
Sperm concentration (×106/ml) 107.25 ± 7.09 42 ± 7.12*  38 ± 6.32* 
Sperm motility (%) 80 ± 1.88 73.75 ± 3.75 64.28 ± 4.80** 
Sperm morphology (%)
Normal 76 60 52
Abnormal‐total 
(tail + head)
24 40**  48* 
Notes. Pearson's chi‐square test was used for evaluation of sperm morphology data. One‐way 
ANOVA and post hoc Tukey's HSD tests were used for evaluation of the other data. Data are repre‐
sented as mean ± SEM.
*p < 0.001, **p < 0.05; significantly different than control. n = 8 for each group. 
TA B L E  3   Effects of paroxetine or 
bupropion on male rats’ sperm parameters
F I G U R E  3  Effects	of	paroxetine	or	bupropion	on	different	indices	of	energy	balance	documented	in	male	rats	(21–90	days).	(a)	Food	
intake, (b) water intake and (c) body weight change (%) (one‐way ANOVA followed by post hoc Tukey's HSD test). n = 8 for each group
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food intake, it was determined that there was an increase in the lev‐
els of pnd 25 to the pnd 40, although it was not significant, and was 
similar to the control group values after pnd 40. In the 69‐day pe‐
riod, bupropion food intake values were observed in parallel with 
the	control	group	(Figure	3a).	For	the	water	intake,	it	was	found	that	
bupropion group values were similar to the control group. In the 
paroxetine group, there was no statistically significant difference in 
the 69‐day period compared to the control group in water intake 
(Figure	3b).	Similarly,	there	was	no	statistically	significant	difference	
between the control group and other groups at body weight change 
for	69‐day	period	(Figure	3c).
3.5 | Effects of paroxetine or bupropion on 
histopathology of testicular tissue
As a result of examination of testicular tissues in the light micro‐
scope, it was determined that there were some differences in the 
testicular tissue in all groups compared to the control group. In the 
sections of the control group, seminiferous tubule structure, Sertoli 
cells	and	interstitial	Leydig	cells	were	normal	(Figure	4a).	When	the	
paroxetine and bupropion groups were evaluated, it was seen that 
there were atrophy in the seminiferous tubules, oedema in the in‐
terstitial area of seminiferous tubules and vacuolisation in the semi‐
niferous tubules epithelium in both groups. Among these changes, 
only interstitial oedema is statistically significant at only bupropion 
group (p < 0.05). Histological damage scores for treatment groups 
are presented in Table 4.
4  | DISCUSSION
Puberty refers to the physical and psychological transition to adult‐
hood as a result of changes in the activation of the hypothalamus 
pituitary	 gonadal	 (HPG)	 axis.	 These	 changes	 occur	 as	 a	 result	 of	
activation in all major elements, including hypothalamus, pituitary 
and gonads (Bianco, 2012). This period starts with the maturation 
of	HPG	axis;	continues	with	phenotypic	changes	specific	to	the	sex,	
growth of the muscles, bones and sexual organs; and ends with the 
F I G U R E  4   Histological illustration of testicular tissues in rats with paroxetine or bupropion treatment. (a) Control group: Spermatogenic 
series cells (black star) and Sertoli cells, basal membrane (black arrow) and interstitial Leydig cells (orange arrow) are distinguished in their 
normal structure. (b, c) Paroxetine group: Seminiferous tubule basal membrane and Leydig cells are normal, but vacuolisation (orange star) 
is distinguished in the seminiferous tubule epithelium and atrophic seminiferous tubule structure (arrow) among the normal‐appearanced 
seminiferous tubules. (d) Bupropion group: Seminiferous tubule epithelium (orange star), basal membrane structure (orange arrow) and 
Leydig cells (black arrow) are observed normally, while prominent interstitial oedema (blue star) is noteworthy. Periodic acid–Schiff (PAS) 
with haematoxylin counterstained Mag. 200×
(b)
(d)
(a)
(c)
TA B L E  4   Histological damage scores for rat exposed to 
paroxetine or bupropion compared with control
Groups Interstitial oedema Vacuolisation Atrophy
Control 0.15 ± 0.08 0.2 ± 0.09 0.05 ± 0.05
Paroxetine 0.35 ± 0.11 0.55 ± 0.14 0.2 ± 0.09
Bupropion 0.6 ± 0.2*  0.45 ± 0.11 0.15 ± 0.08
Notes. One‐way ANOVA and post hoc Tukey's HSD tests were used for 
evaluation of the data. Data are represented as mean ± SEM. n = 20 for 
each group.
*p < 0.05; significantly different than control. 
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achievement	of	full	reproduction	capacity	(Gonc,	2009).	Our	study	
was the first to show that postnatal long‐term exposure to the SSRI 
paroxetine or bupropion led to a delay slightly in male rats’ puberty 
onset. Paroxetine treatment also did not result in any changes in pu‐
bertal	weight,	FSH,	LH	and	leptin	levels.	However,	bupropion	treat‐
ment increased LH and testosterone levels significantly but did not 
change	FSH	and	leptin	levels.	Neither	paroxetine	nor	bupropion	did	
not change water and food intake, body weight and reproductive or‐
gans weights. Also, paroxetine and bupropion treatment decreased 
sperm count and resulted in rise in abnormal sperm rate and histo‐
pathological changes in testicular tissue. In addition, sperm motility 
decreased only in bupropion treatment.
In relation to the effects of paroxetine treatment on the puberty 
onset, there has been only two prenatal SSRI treatment studies 
(dos Santos et al., 2016; Moore et al., 2015). In one of these studies, 
prenatal fluoxetine treatment did not change puberty onset and pu‐
bertal weight (Moore et al., 2015). However, in another study, pre‐
natal and lactational exposure to fluoxetine delayed puberty onset 
in female rats (dos Santos et al., 2016). The effect of serotonin on 
the reproductive system is thought to be via the hypothalamus and 
the studies indicate the presence of synapses between serotonergic 
neurons	and	GnRH	neurons.	It	is	thought	that	a	certain	level	of	sero‐
tonin is needed to maintain the normal activity of the gonadal axis, 
and	this	is	due	to	the	facilitating	effect	of	serotonin	on	the	HPG	axis.	
Another possibility is that serotonin acts as a stimulant or inhibitor 
with	different	serotonergic	receptors	on	the	HPG	axis	(Gore,	2002).	
Studies	on	the	effects	of	5‐HT	on	GnRH	secretion	have	been	shown	
that	5‐HT	stimulates	GnRH	secretion	by	the	activation	of	5‐HT2C, 5‐
HT4 and 5‐HT7 receptors and inhibits the activation of 5‐HT1A recep‐
tor (Moran et al., 2013). 5‐HT can act as both stimulant and inhibitor 
of	GnRH	secretion	due	to	sex	and	5‐HT	receptor	signalling	pathways	
(Wada et al., 2006). In our study, paroxetine treatment caused a 
delay slightly in pubertal timing. Possibly, paroxetine increased 5‐HT 
levels by its mechanism, and increased 5‐HT might have acted as an 
inhibitor on pubertal timing. Interestingly, it seems that 5‐HT has an 
inhibitor	effect	on	GnRH	in	this	study	but	testosterone	and	LH	lev‐
els increased slightly; however, they are not significant. There is no 
mechanism of action to explain this paradoxal effect.
Similarly, postnatal bupropion treatment led to delay slightly 
in puberty onset and did not change pubertal weight. There was 
only one study about bupropion treatment but it was relevant to 
prenatal treatment. Bupropion exposure throughout pregnancy 
led to an advanced vaginal opening (i.e., earlier pubertal onset) in 
the female rats. Because of bupropion effects on dopamine trans‐
porter (DAT) as an inhibitor, hence, dopamine levels increase, and 
then, maternal care behaviour is affected negatively. As a result, 
puberty onset accelerates (De Long et al., 2013). In relation to 
the effects of postnatal bupropion treatment on puberty onset 
and pubertal weight, any mechanism of action does not exist. The 
timing of puberty has been identified as a crucial factor in men‐
tal health, with deviations from normative development placing 
an individual at greater risk of psychopathology. Recent studies 
suggested that deviations from the normative timing (i.e., either 
early or late maturation) are associated with negative results such 
as substance abuse, disruptive behaviour disorders and increased 
symptoms of depression (Cowan & Richardson, 2018). Consistent 
with our results, these situations indicate that exposure to paroxe‐
tine or bupropion during early life may cause disruptive alterations 
in adolescents’ life.
5‐HT regulates feeding behaviour through interaction between 
its various receptors. Serotonergic roles of presynaptic 5‐HT1A, 5‐
HT1B, 5‐HT2A and 5‐HT2C receptors on nutrition were investigated. 
5‐HT1B and 5‐HT2C were thought to play a role in the formation 
of anorectic response by inhibiting feeding behaviour (Magalhaes 
et al., 2010). 5‐HT1B stimulation reduces neuropeptide Y (NPY)/
agouti‐related peptide (AgRP) neuronal activity and therefore tonic 
GABAergic	inhibition	of	proopiomelanocortin	(POMC)/cocaine	and	
amphetamine‐regulated transcript (CART) neurons, which in turn are 
activated by 5‐HT2C stimulation. These circuits synergistically con‐
tribute to the anorectic effects of serotonergic receptors in the hy‐
pothalamus (da Silva et al., 2019). In animal studies, it was suggested 
that chronic paroxetine treatment led to a decrease in body weight 
(Amodeo et al., 2015; de Jong et al., 2006; Konkle & Bielajew, 1999; 
Konkle, Sreter, Baker, & Bielajew, 2003). However, in this study, we 
reported that long‐term paroxetine treatment did not lead to a sig‐
nificant change in body weight. Compatible with unchanged body 
weight values, there was also no significant change in food intake. 
It can be thought that low dose level (3.6 mg/kg) paroxetine could 
have not induced an anorectic response. If paroxetine treatment 
affected 5‐HT1B/2C receptors, there would be a decrease in food in‐
take. Thereby, also body weight would decrease. On the other hand, 
human studies suggest that chronic paroxetine treatment results in 
weight gain (Amodeo et al., 2015). The reason for this paradoxical 
effect is unknown.
It has been reported that bupropion does not cause an in‐
crease in body weight, and any significant changes in calorie 
intake, and appetite in studies on nutrition, and body energy con‐
dition (Demyttenaere & Jaspers, 2008). It has also been reported 
that it has no hypophagic effect (Liu, Connoley, Heal, & Stock, 
2004). Compatible with this condition, in the present study, bu‐
propion did not lead to any significant changes in body weight or 
food intake.
The secretion of antidiuretic hormone (ADH) in reply to osmotic 
stimuli is well reported but the neurotransmitter mechanisms that 
mediate these responses are less well understood. There is some 
evidence to offer that 5‐HT has a physiological significance in os‐
moregulated ADH secretion since lesion of 5‐HT cell bodies in the 
brain stem raphe nuclei blocks the normal increase in plasma ADH in 
response to water deprivation and to hyperosmotic infusion. Animal 
studies have reported that an acute rise in central 5‐HT neurotrans‐
mission	 causes	 to	 a	 rise	 in	 plasma	ADH	 (Faull,	 Charlton,	Butler,	&	
Baylis, 1993). In this study, paroxetine treatment caused a decrease 
in water intake although it was not statistically significant. As a re‐
sult, it can be concluded that the increase in the levels of 5‐HT due 
to paroxetine treatment might have stimulated the release of ADH 
and consequently decreased water intake.
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Leptin, which plays an important role in puberty and repro‐
duction, is a peptide produced mainly in white adipose tissue and 
transmits the peripheral adipose reserve information to the brain 
(Smeets, 2015). Leptin plays an important role in the regulation of 
energy homeostasis, neuroendocrine and immune functions, glu‐
cose and lipid metabolism (Park & Ahima, 2015). Studies have shown 
that the level of leptin is proportional to body fat and body mass 
index but many other factors are involved in the regulation of leptin 
(Frederich	et	al.,	1995;	Ma	et	al.,	1996).	In	the	present	study,	parox‐
etine or bupropion treatment also did not change leptin levels sig‐
nificantly. In studies performed on humans, it was determined that 
chronic paroxetine treatment had no effect on serum leptin levels 
(Hinze‐Selch et al., 2000; Janssen, Touw, Schweitzer, & Waldinger, 
2014; Ozsoy, Besirli, Abdulrezzak, & Basturk, 2014), but effects in 
rodents remained unknown. Bupropion also had no effect on leptin 
levels, and this situation was normal, because, as mentioned above, 
it has no hypophagic effect. Thereby, as food intake and body weight 
did not change, hence, leptin did not.
Spermatogenesis in mammals includes many events that occur 
in	the	HPG	axis.	The	production	of	spermatozoa	is	regulated	by	the	
hormones luteinising hormone (LH) and follicle‐stimulating hormone 
(FSH),	which	act	on	Leydig	and	Sertoli	cells	respectively.	Both	hor‐
mones are secreted in response to gonadotropin‐releasing hormone 
(GnRH)	production	(Aragón	et	al.,	2005).	Sertoli	cells	are	stimulated	
by	secretion	of	FSH	from	the	pituitary	gland,	and	spermatogenesis	
occurs in germ cells at seminiferous tubules. As a result of LH se‐
cretion, Leydig cells are stimulated, and testosterone is synthesised. 
Therefore,	 LH,	 FSH	 and	 testosterone	 are	 used	 as	markers	 of	 tes‐
ticular activity and spermatogenesis in men. The anomalies or dis‐
orders in sperm production are manifested by distortions in sperm 
number and motility and may cause infertility (Sofikitis et al., 2008). 
5‐HT receptors are known to exist in the testis and epididymis, and 
they are responsible for regulating testicular blood flow in the tes‐
tis and sperm maturation in epididymis. 5‐HT receptors in Sertoli 
cells	 are	 thought	 to	 play	 a	 role	 in	 spermatogenesis	 (Syed,	Gomez,	
& Hecht, 1999). Therefore, 5‐HT may act on regulation of sperm 
motility and density. 5‐HT induces corticotropin‐releasing hormone 
(CRH) secretion via 5‐HT2 receptors in Leydig cells and stimulates 
phosphoinositol hydrolysis. As a result, an inhibitory effect on LH 
and	 testosterone	 secretion	 occurs	 (Frungieri	 et	 al.,	 1999).	 Also,	 it	
was suggested that SSRIs bind to the sulphydryl group in the sperm 
membrane and produce a spermicidal effect by interacting with 
phospholipids (Kumar et al., 2006). In addition, it has been reported 
that increased 5‐HT levels have negative effects on semen param‐
eters	and	may	cause	sperm	dysfunction	 (Gonzales,	Garcia‐Hjarles,	
& Velasquez, 1992; Ortiz et al., 2010). Compatible with our results, 
in many studies, it was suggested that paroxetine and other some 
SSRIs can affect sperm parameters negatively (Bataineh & Daradka, 
2007; Erdemir et al., 2014; Inass et al., 2005; Jahromy & Moghadam, 
2014; Kumar et al., 2006). In some of these studies, it was reported 
that serum gonadotropin levels also decreased significantly with 
sperm parameters. However, there was no change in gonadotropins 
levels in our study. Some other studies have shown that SSRIs do 
not affect serum LH levels contrary to these results (Bell, Shipman, 
Bystritsky, & Haifley, 2006; Schlösser et al., 2000). We concluded 
that	 unchanged	 FSH	 and	 LH	 levels	 suggest	 that	 paroxetine	 treat‐
ment during juvenile development and adulthood does not alter 
HPG	axis	function	but	 increased	 levels	of	5‐HT	caused	changes	 in	
sperm parameters and also testicular histopathology probably due 
to direct toxic effect of the paroxetine on the testes; hence, it can 
affect male fertility directly, because male factor infertility is usually 
diagnosed by the assessment of sperm concentration, sperm motil‐
ity, and sperm morphology (Atli et al., 2017).
In a study, it was observed that serum LH levels increased, and 
FSH	 levels	 remained	 unchanged	 as	 a	 result	 of	 30	days	 of	 chronic	
bupropion treatment (Cavariani et al., 2015). In a study conducted 
by	Roshdy	and	Fyiad	(2010),	it	was	reported	that	chronic	bupropion	
treatment caused a significant sperm anomaly in mice. Bupropion 
has been reported to adversely affect sperm motility. The loss of 
motility in the spermatozoa is closely related to productivity in men 
because it prevents the entry of spermatozoa into the oocyte. In 
vitro studies have shown that dopamine and adrenergic agonists 
stimulate chloride secretion with epididymal epithelial cells and that 
sympathetic innervation changes the epididymal fluid protein com‐
position (Cavariani et al., 2015). Both factors are important factors in 
obtaining sperm motility and productivity. The loss of sperm motility 
in animals with bupropion treatment is thought to be caused by the 
modification of the epididymal ionic/protein luminal composition 
with sympathomimetic effect of bupropion. Although bupropion 
treatment revealed loss of sperm quality, it is known that bupro‐
pion has no effect on fertility in male rats. The decrease in sperm 
quality is thought to be masked by high reproductive activity in rats 
(Cavariani et al., 2015). In a study by Tanrikut and Schlegel (2007) on 
human effects, it was reported that bupropion treatment resulted in 
a decrease in sperm motility and number, and after the interruption 
of treatment, sperm concentration and motility values returned to 
normal. In the study performed by Kankash, Shariati, and Khatamsaz 
(2014),	 it	was	determined	that	serum	LH	and	FSH	levels	 increased	
significantly compared to the control group as a result of chronic bu‐
propion treatment. Similarly, in the present study, bupropion treat‐
ment led to an increase in LH and testosterone levels. As mentioned 
above, bupropion shows its antidepressant effect by inhibiting do‐
pamine and norepinephrine reuptake. Norepinephrine is thought to 
result	in	the	formation	of	pulsatile	GnRH	secretion	rather	than	con‐
trolling it (Herbison, 1997). The stimulation or inhibition of norepi‐
nephrine	on	the	HPG	axis	depends	entirely	on	steroids	presence.	In	
various	studies,	norepinephrine	suppressed	GnRH	and	LH	secretion	
in ovariectomised rats but then regarding the progesterone/oestro‐
gen treatment, it was observed that it stimulated in ovariectomised 
rats	 (Genazzani,	Bernardi,	Monteleone,	Luisi,	&	Luisi,	2000).	 In	the	
present study, probably bupropion led to an increase in norepineph‐
rine levels. Increasing norepinephrine levels resulted in an increase 
in	 GnRH	 and	 then	 LH	 and	 finally	 testosterone	 levels.	 In	 addition,	
the increased serum LH levels that accompany the decreased sperm 
concentration and motility and increased abnormal sperm rate can 
be attributed to the compensatory mechanisms against this decrease 
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by inducing spermatogenesis by this hormone. Also, human studies 
have shown that serum LH levels have an inverse/negative correla‐
tion with sperm concentration (Atli et al., 2017).
In the histopathological examination, it was seen that there 
were atrophy in the seminiferous tubules, oedema in the inter‐
stitial area of seminiferous tubules and vacuolisation in the semi‐
niferous tubules epithelium in both groups. Similarly, previously it 
was suggested that SSRIs may lead to the distortions in testicular 
tissue (Aggarwal, Jethani, Rohatgi, & Kalra, 2012; Atli et al., 2017; 
Yakubu & Atoyebi, 2018). It was reported that 5‐HT plays a role 
on testis seminiferous tubules, accessory reproductive organs and 
epithelial cells by 5‐HT receptor type‐2 (5‐HT 2R), and stimulates 
smooth muscle contraction. Therefore, it affects sperm produc‐
tion and maturation process. Excessive free 5‐HT in the periphery 
perpetually induces the smooth muscle of blood vessels directly 
through 5‐HT2R or indirectly by thromboxane A2. This effect may 
increase vasoconstriction and smooth muscle proliferation, leading 
to microcirculation distortions. 5‐HT is known to be a powerful in‐
flammatory mediator. High levels of 5‐HT in the hypoxic conditions 
can stimulate testicular interstitial tissue inflammation and fibro‐
sis, resulting in a decrease in blood supply and atrophy of Leydig 
cells (Aggarwal et al., 2012). We suggested that this atrophy might 
occur in seminiferous tubules indicated by another study (Atli et 
al., 2017). Also, in one study, paroxetine treatment‐induced vacu‐
ole formation was reported (Inass et al., 2005). Together with the 
damages induced by paroxetine in the testicle, it is possible to as‐
sociate degenerative findings detected in testicular tissue with the 
elevated 5‐HT levels. In parallel with this result, sperm concentra‐
tion decreased and sperm abnormal rate increased in paroxetine 
group. In relation to this result, it was reported that excess levels 
or absence of serotonin may cause disorders in sperm parameters 
(Atli et al., 2017).
In relation to the bupropion effects on the histopathology of tes‐
tis, seminiferous tubule epithelium, basal membrane structure and 
Leydig cells were observed normally, while prominent interstitial oe‐
dema was noteworthy. Various studies have indicated that the levels 
of interstitial fluid can be increased by a variety of factors, such as 
endogenous LH (Porter, Shetty, & Meistrich, 2006). In our study, in‐
terstitial oedema may have occurred due to increased LH levels in 
bupropion group.
In summary, our study is the first to show that paroxetine or 
bupropion may lead to the delay in pubertal timing although both 
antidepressants did not alter body weight and food intake. The re‐
sults derived from this study suggest that bupropion or paroxetine 
exposure during puberty may impair male reproduction in humans. 
However, this study is based on an animal model, and more clinical 
studies are needed in order to evaluate the effects of these antide‐
pressants on puberty and reproductive parameters.
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